Otsuka's novel TB drug filed in Japan
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has filed the second approval application worldwide for delamanid (OPC-67683), its novel oral molecule for multidrug-resistant tuberculosis (MDR-TB).